cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/ygc-wbb-9wn
title: Hydrachna O. F. Müller, 1776

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/udt3-22rg
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.3535/7qm-fp3-wd6
title: Pallenopsis Wilson, 1881

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/v20-069-rv3
title: Mesobuthus Vachon, 1950

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/b3wp-thze
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.6084/m9.figshare.27861620
title: Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis

description: We conducted a meta-analysis of published randomized controlled trials to compare the effectiveness and safety of eribulin versus paclitaxel for patients with breast cancer. We systematically searched multiple databases including Cochrane, PubMed, Medline, and Embase. The primary outcomes analyzed were overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), and adverse events (AEs). These outcomes were evaluated using RevMan5.3 software. A total of 5 studies were included in the analysis. Compared to paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs not only extended the overall survival of patients but also improved the disease control rate (DCR) [risk ratio (RR) 0.98, (95% confidence intervals (CI): 0.70, 1.38), <i>p</i> = 0.92]. Hematological system diseases [RR 1.18 (95% CI: 1.07, 1.31), <i>p</i> = 0.002] were the most frequently observed adverse event with eribulin, while paclitaxel was more likely to cause nervous system lesion [RR 0.66 (95% CI: 0.54, 0.80), <i>p</i> &lt; 0.0001]. Compared with paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs can also prolong the PFS and OS of BC patients. Our recommendation is to use eribulin plus other chemotherapy drugs to treat advanced BC and to continuously monitor and manage the drug-related adverse events. In order to further explore the efficacy and safety of eribulin and paclitaxel in treating breast cancer, our study conducted the first meta-analysis on this topic. The objective was to compare the effectiveness of eribulin and paclitaxel and provide valuable insights for clinicians. Eribulin plus other chemotherapy drugs significantly prolonged OS or improved DCR in patients with BC, which was no statistical difference compared with paclitaxel (P＞0.05). Eribulin not only can be used as a first-line treatment for advanced breast cancer but also can be used to treat patients who are resistant to taxane, so the choice is wider. In terms of adverse drug reactions, Eribulin is easy to cause hematological system diseases, especially neutropenia, while paclitaxel is prone to cause nervous system lesions. Both of them can cause impaired digestive function and skin and hair damage. Our recommendation is to select appropriate chemotherapy drugs to treat different states of BC patients and to prevent and manage AEs after using drugs.
DOI: 10.6084/m9.figshare.27861620.v1
title: Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis

description: We conducted a meta-analysis of published randomized controlled trials to compare the effectiveness and safety of eribulin versus paclitaxel for patients with breast cancer. We systematically searched multiple databases including Cochrane, PubMed, Medline, and Embase. The primary outcomes analyzed were overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), and adverse events (AEs). These outcomes were evaluated using RevMan5.3 software. A total of 5 studies were included in the analysis. Compared to paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs not only extended the overall survival of patients but also improved the disease control rate (DCR) [risk ratio (RR) 0.98, (95% confidence intervals (CI): 0.70, 1.38), <i>p</i> = 0.92]. Hematological system diseases [RR 1.18 (95% CI: 1.07, 1.31), <i>p</i> = 0.002] were the most frequently observed adverse event with eribulin, while paclitaxel was more likely to cause nervous system lesion [RR 0.66 (95% CI: 0.54, 0.80), <i>p</i> &lt; 0.0001]. Compared with paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs can also prolong the PFS and OS of BC patients. Our recommendation is to use eribulin plus other chemotherapy drugs to treat advanced BC and to continuously monitor and manage the drug-related adverse events. In order to further explore the efficacy and safety of eribulin and paclitaxel in treating breast cancer, our study conducted the first meta-analysis on this topic. The objective was to compare the effectiveness of eribulin and paclitaxel and provide valuable insights for clinicians. Eribulin plus other chemotherapy drugs significantly prolonged OS or improved DCR in patients with BC, which was no statistical difference compared with paclitaxel (P＞0.05). Eribulin not only can be used as a first-line treatment for advanced breast cancer but also can be used to treat patients who are resistant to taxane, so the choice is wider. In terms of adverse drug reactions, Eribulin is easy to cause hematological system diseases, especially neutropenia, while paclitaxel is prone to cause nervous system lesions. Both of them can cause impaired digestive function and skin and hair damage. Our recommendation is to select appropriate chemotherapy drugs to treat different states of BC patients and to prevent and manage AEs after using drugs.
DOI: 10.3535/453-0g5-yj5
title: Torrenticola Piersig, 1896

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/4w8-swh-cyx
title: Torrenticolidae Thor, 1902

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/gyka-m6tc
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.3535/gg2-w39-rdd
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/k7ba-c8zz
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.6084/m9.figshare.27828415
title: The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

description: In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options. The goal of this podcast is to help doctors and patients learn about and discuss the different androgen deprivation therapy (ADT) options used to treat advanced prostate cancer. Advanced prostate cancer is a type of cancer that started in the prostate and has spread outside of the prostate. Prostate cancers generally need the male sex hormone, called testosterone, to grow. Treatment for advanced prostate cancer often includes lowering testosterone levels through medicines called ADTs. The authors discuss the HERO trial, which looked at relugolix (the only ADT taken orally [by mouth]) and compared it with another type of ADT called leuprolide, which is given by injection at a doctor's office. The authors discuss the effectiveness and side effects of these. A PDF version of this infographic is available as supplemental material.
DOI: 10.6084/m9.figshare.27828415.v2
title: The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

description: In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options. The goal of this podcast is to help doctors and patients learn about and discuss the different androgen deprivation therapy (ADT) options used to treat advanced prostate cancer. Advanced prostate cancer is a type of cancer that started in the prostate and has spread outside of the prostate. Prostate cancers generally need the male sex hormone, called testosterone, to grow. Treatment for advanced prostate cancer often includes lowering testosterone levels through medicines called ADTs. The authors discuss the HERO trial, which looked at relugolix (the only ADT taken orally [by mouth]) and compared it with another type of ADT called leuprolide, which is given by injection at a doctor's office. The authors discuss the effectiveness and side effects of these. A PDF version of this infographic is available as supplemental material.
DOI: 10.6084/m9.figshare.27852178
title: The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab

description: Bevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area. A total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment. Treatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis. A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC. Metastatic colorectal cancer (mCRC), which has spread to other organs (such as the liver or lungs), is commonly treated with a combination of targeted therapy and chemotherapy. Targeted therapy specifically acts on molecular targets on cells, aiming to inhibit or eliminate tumor growth. Bevacizumab is a key targeted drug in both first- and second-line treatments for mCRC (first-line treatment refers to the initial intervention strategy, while second-line treatment is considered when the tumor progresses due to chemotherapy resistance or after the failure of the initial treatment). However, after first-line treatment fails, the duration of tumor non-progression is often shorter than that achieved with first-line treatment. Therefore, distinguishing the differences in first-line treatment efficacy among patients is crucial for developing personalized treatment plans. Previous studies indicate that bevacizumab may cause muscle tissue atrophy. Quantitative Computed Tomography (QCT) can measure various body composition parameters, such as muscle area and visceral fat area. This study, which used QCT to track body composition changes in patients receiving bevacizumab with first-line chemotherapy, found that patients who lost over 6.6% of muscle mass during treatment had poorer outcomes. Thus, changes in body composition can effectively predict treatment efficacy. Currently, the dosage of bevacizumab is based on body surface area (BSA), calculated using height and weight. However, patients with the same BSA may have differing body composition parameters. By accurately measuring body composition changes, QCT could assist clinicians in adjusting bevacizumab dosages or implementing interventions, enabling patients to achieve a more prolonged state of disease stability. The changes in body compositions induced by first-line chemotherapy based on bevacizumab can serve as prognostic indicators for mCRC patients, with the potential to provide auxiliary evidence for personalized dosing selection of bevacizumab in future clinical endeavors.
DOI: 10.6084/m9.figshare.27852178.v1
title: The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab

description: Bevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area. A total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment. Treatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis. A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC. Metastatic colorectal cancer (mCRC), which has spread to other organs (such as the liver or lungs), is commonly treated with a combination of targeted therapy and chemotherapy. Targeted therapy specifically acts on molecular targets on cells, aiming to inhibit or eliminate tumor growth. Bevacizumab is a key targeted drug in both first- and second-line treatments for mCRC (first-line treatment refers to the initial intervention strategy, while second-line treatment is considered when the tumor progresses due to chemotherapy resistance or after the failure of the initial treatment). However, after first-line treatment fails, the duration of tumor non-progression is often shorter than that achieved with first-line treatment. Therefore, distinguishing the differences in first-line treatment efficacy among patients is crucial for developing personalized treatment plans. Previous studies indicate that bevacizumab may cause muscle tissue atrophy. Quantitative Computed Tomography (QCT) can measure various body composition parameters, such as muscle area and visceral fat area. This study, which used QCT to track body composition changes in patients receiving bevacizumab with first-line chemotherapy, found that patients who lost over 6.6% of muscle mass during treatment had poorer outcomes. Thus, changes in body composition can effectively predict treatment efficacy. Currently, the dosage of bevacizumab is based on body surface area (BSA), calculated using height and weight. However, patients with the same BSA may have differing body composition parameters. By accurately measuring body composition changes, QCT could assist clinicians in adjusting bevacizumab dosages or implementing interventions, enabling patients to achieve a more prolonged state of disease stability. The changes in body compositions induced by first-line chemotherapy based on bevacizumab can serve as prognostic indicators for mCRC patients, with the potential to provide auxiliary evidence for personalized dosing selection of bevacizumab in future clinical endeavors.
DOI: 10.3535/83s-z5t-5mc
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/9g5-k4f-lk5
title: Hydrodroma C. L. Koch, 1837

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/ttu5-st6e
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.3535/58x-bna-act
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/v2rh-yex2
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.6084/m9.figshare.28052709
title: Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma

description: The co-occurrence of PD-L1 positivity and EGFR mutations in advanced NSCLC often limits EGFR-TKIs effectiveness, with unclear mechanisms. We analyzed 103 treatment-naive EGFR-mutant LUAD patients from three centers, assessing PD-L1 expression and performing NGS analysis. SMO mutations and MET amplification were significantly higher in the PD-L1 ≥ 1% group versus PD-L1 &lt; 1% group (SMO: 8% vs. 0%, <i>p</i> = 0.048; MET: 18% vs. 7%, <i>p</i> = 0.023). The DNA Damage Response and Repair (DDR) pathogenic deficiency mutations, along with biological processes and signaling pathways related to DNA recombination, cell cycle transition and abnormal phosphorylation, were more prevalent in the PD-L1 ≥ 1% group. PIK3CA and RARA clonal alterations were more common in PD-L1 &lt; 1% group, while TP53 clonal mutations predominated in PD-L1 ≥ 1% group. Retrospective analysis showed EGFR-TKIs plus chemotherapy extended median PFS by 9.8 months, potentially overcoming EGFR-TKI monotherapy resistance. This study elucidates the genomic characteristics of PD-L1-induced resistance to EGFR-TKIs. For patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy combining EGFR-TKIs with chemotherapy may offer a more effective alternative. This study looked at lung cancer patients who have two important characteristics: changes in a gene called EGFR and a protein called PD-L1. While there are drugs (EGFR-TKIs) that target EGFR mutations, they don’t always work well when PD-L1 is also present. The researchers studied 103 lung cancer patients to understand why this happens. They found that patients with higher PD-L1 levels had different genetic patterns, including more changes in genes that affect DNA repair and cell growth. Importantly, they discovered that combining standard EGFR-targeting drugs with chemotherapy helped patients respond better to treatment, extending the time before their cancer got worse by almost 10 months. This suggests that patients with both EGFR mutations and PD-L1 might benefit more from a combination treatment approach rather than using EGFR-targeting drugs alone.
DOI: 10.6084/m9.figshare.28052709.v1
title: Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma

description: The co-occurrence of PD-L1 positivity and EGFR mutations in advanced NSCLC often limits EGFR-TKIs effectiveness, with unclear mechanisms. We analyzed 103 treatment-naive EGFR-mutant LUAD patients from three centers, assessing PD-L1 expression and performing NGS analysis. SMO mutations and MET amplification were significantly higher in the PD-L1 ≥ 1% group versus PD-L1 &lt; 1% group (SMO: 8% vs. 0%, <i>p</i> = 0.048; MET: 18% vs. 7%, <i>p</i> = 0.023). The DNA Damage Response and Repair (DDR) pathogenic deficiency mutations, along with biological processes and signaling pathways related to DNA recombination, cell cycle transition and abnormal phosphorylation, were more prevalent in the PD-L1 ≥ 1% group. PIK3CA and RARA clonal alterations were more common in PD-L1 &lt; 1% group, while TP53 clonal mutations predominated in PD-L1 ≥ 1% group. Retrospective analysis showed EGFR-TKIs plus chemotherapy extended median PFS by 9.8 months, potentially overcoming EGFR-TKI monotherapy resistance. This study elucidates the genomic characteristics of PD-L1-induced resistance to EGFR-TKIs. For patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy combining EGFR-TKIs with chemotherapy may offer a more effective alternative. This study looked at lung cancer patients who have two important characteristics: changes in a gene called EGFR and a protein called PD-L1. While there are drugs (EGFR-TKIs) that target EGFR mutations, they don’t always work well when PD-L1 is also present. The researchers studied 103 lung cancer patients to understand why this happens. They found that patients with higher PD-L1 levels had different genetic patterns, including more changes in genes that affect DNA repair and cell growth. Importantly, they discovered that combining standard EGFR-targeting drugs with chemotherapy helped patients respond better to treatment, extending the time before their cancer got worse by almost 10 months. This suggests that patients with both EGFR mutations and PD-L1 might benefit more from a combination treatment approach rather than using EGFR-targeting drugs alone.
DOI: 10.3535/7me-hyw-v33
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/knm-skt-lja
title: Eurycyde acanthopus Stock, 1979

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/v9t9-dyx3
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.48597/znx3-jnnt
title: Measurement of Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.3535/7yh-5re-q01
title: Lebertia Neuman, 1880

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/yvp-rmm-s5k
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.48597/82mf-p2f5
title: Inorganics in precipitation at Løken

description: Measurement of Inorganics in precipitation at Løken
DOI: 10.17026/dans-2cs-q5eu
title: PAN-00048734 - large single looped ring buckle

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00048734&lt;/p&gt;
description: Modified: 2019-10-28T08:54:24+01:00
DOI: 10.3535/n2m-s13-7bf
title: Arrenuridae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/r9r-9d4-at2
title: Limnesia C. L. Koch, 1836

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/s1k-ymz-mcn
title: Limnesia C. L. Koch, 1836

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/zht-22q-f49
title: Athienemanniidae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.15468/dl.x9hauw
title: Occurrence Download

description: A dataset containing 39729 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Aquilegia canadensis L."
 ]
}

 The dataset includes 39729 records from 281 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0087013-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/5yh-92r-qgz
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.